The diagnostic utility of autoantibodies in adult and juvenile myositis

Current Opinion in Rheumatology

Volumn 25, Issue 6, 2013, Pages 772-777

  Tansley, Sarah L ^a   Betteridge, Zoe E ^b   McHugh, Neil J ^a  

^a ROYAL NATIONAL HOSPITAL FOR RHEUMATIC DISEASES   (United Kingdom)

^b UNIVERSITY OF BATH   (United Kingdom)

Author keywords

Autoantibody; Diagnosis; Myositis; Prognosis

Indexed keywords

AMINO ACID TRANSFER RNA LIGASE; ANTI TRANSCRIPTION INTERMEDIARY FACTOR 1 GAMMA; AUTOANTIBODY; MYOSITIS SPECIFIC AUTOANTIBODY; NUCLEAR FACTOR; NUCLEAR MATRIX PROTEIN; NUCLEAR MATRIX PROTEIN 2; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL FEATURE; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; IMMUNOFLUORESCENCE; JUVENILE DERMATOMYOSITIS; PHENOTYPIC VARIATION; PRIORITY JOURNAL; PROGNOSIS; SCREENING TEST;

ADULT; AUTOANTIBODIES; AUTOANTIGENS; BIOLOGICAL MARKERS; CHILD; DERMATOMYOSITIS; HUMANS; PROGNOSIS;

EID: 84885293889     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/01.bor.0000434664.37880.ac     Document Type: Article

References (40)

1. Sontheimer RD. Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sine myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness? J Am Dermatol 2002; 46:626-636
2. .Koga T, Fujikawa K, Horai Y, et al. The diagnostic utility of antimelanoma differentiation-Associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM. Rheumatology 2012; 51:1278-1284
3. Sato S, Hoshino K, Satoh T, et al. RNA helicase encoded by melanoma differentiation-Associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: Association with rapidly progressive interstitial lung disease. Arthritis Rheum 2009; 60:2193-2200
4. Pachman LM, Hayford JR, Chung A, et al. Juvenile dermatomyositis at diagnosis: Clinical characteristics of 79 children. J Rheumatol 1998; 25: 1198-1204
5. Bowyer SL, Blane CE, Sullivan DB, Cassidy JT. Childhood dermatomyositis: Factors predicting functional outcome and development of dystrophic calcification. J Pediatr 1983; 103:882-888
6. .Casciola-Rosen L, Mammen AL. Myositis autoantibodies. Curr Opin Rheumatol 2012; 24:602-608
7. Gunawardena H, Betteridge ZE, McHugh NJ. Myositis-specific autoantibodies: Their clinical and pathogenic significance in disease expression. Rheumatology 2009; 48:607-612
8. Gunawardena H, Wedderburn LR, North J, et al. Clinical associations of autoantibodies to a p155/140 kDa doublet protein in juvenile dermatomyositis. Rheumatology 2007; 47:324-328
9. Pluk H, van Engelen BG, Pruijn GJM. Anti-Mup44: The first inclusion body myositis-specific autoantibody. In: Conrad K, editor. Autoantigens, autoantibodies, autoimmunity. Dresden; 2011. p. 210
10. Salajegheh M, Lam T, Greenberg SA. Autoantibodies against a 43 KDa muscle protein in inclusion body myositis. PLoS One 2011; 6:e20266
11. .Pluk H, van Hoeve BJA, van Dooren SHJ, et al. Autoantibodies to cytosolic 50-nucleotidase 1A in inclusion body myositis. Ann Neurol 2013; 73:397-407
12. .Tansley SL, McHugh NJ, Wedderburn LR. Adult and juvenile dermatomyositis: Are the distinct clinical features explained by our current understanding of serological subgroups and pathogenic mechanisms? Arthritis Res Ther 2013; 15:211
13. Hoshino K, Muro Y, Sugiura K, et al. Anti-MDA5 and anti-TIF1-Antibodies have clinical significance for patients with dermatomyositis. Rheumatology 2010; 49:1726-1733
14. Fiorentino D, Chung L, Zwerner J, et al. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): A retrospective study. J Am Acad Dermatol 2011; 65:25-34
15. Hall JC, Casciola-Rosen L, Samedy L-A, et al. Anti-MDA5-Associated dermatomyositis: Expanding the clinical spectrum. Arthritis Care Res 2013; 65:1307-1315
16. Muro Y, Ishikawa A, Sugiura K, Akiyama M. Clinical features of anti-TIF1-Alpha antibody-positive dermatomyositis patients are closely associated with coexistent dermatomyositis-specific autoantibodies and anti-TIF1-gamma or anti-Mi-2 autoantibodies. Rheumatology 2012; 51:1508-1513
17. .Hamaguchi Y, Fujimoto M, Matsushita T, et al. Common and distinct clinical features in adult patients with anti-Aminoacyl-TRNA synthetase antibodies: Heterogeneity within the syndrome. PLoS One 2013; 8:e60442
18. Labirua-Iturburu A, Selva-O'Callaghan A, Vincze M, et al. Anti-PL-7 (antithreonyl-TRNA synthetase) antisynthetase syndrome: Clinical manifestations in a series of patients from a European multicenter study (EUMYONET) and review of the literature. Medicine 2012; 91:206-211
19. Dupont S, Mamidi A, Cordenonsi M, et al. FAM/USP9x, a deubiquitinating enzyme essential for TGFbeta signaling, controls Smad4 monoubiquitination. Cell 2009; 136:123-135
20. Takahashi K, Yoshida N, Murakami N, et al. Dynamic regulation of p53 subnuclear localization and senescence by MORC3. Mol Biol Cell 2007; 18:1701-1709
21. Targoff IN. Autoantibodies in polymyositis. Rheum Dis Clin North Am 1992; 18:455-482
22. Watanabe K, Handa T, Tanizawa K, et al. Detection of antisynthetase syndrome in patients with idiopathic interstitial pneumonias. Respir Med 2011; 105:1238-1247
23. .Aggarwal R, Cassidy E, Fertig N, et al. Patients with non-Jo-1 antitRNAsynthetase autoantibodies have worse survival than Jo-1 positive patients. Ann Rheum Dis 2013. [Epub ahead of print]
24. .Benjamin Larman H, Salajegheh M, Nazareno R, et al. Cytosolic 50-nucleotidase 1A autoimmunity in sporadic inclusion body myositis. Ann Neurol 2013; 73:408-418
25. .Labrador-Horrillo M, Martinez MA, Selva-O'Callaghan A, et al. Anti-TIF1 antibodies (antip155) in adult patients with dermatomyositis: Comparison of different diagnostic assays. ARD 2012; 71:993-996
26. .Ishikawa A, Muro Y, Sugiura K, Akiyama M. Development of an ELISA for detection of autoantibodies to nuclear matrix protein 2. Rheumatology 2012; 51:1181-1187
27. Mammen AL, Chung T, Christopher-Stine L, et al. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statinassociated autoimmune myopathy. Arthritis Rheum 2011; 63:713-721
28. Benveniste O, Drouot L, Jouen F, et al. Correlation of antisignal recognition particle autoantibody levels with creatine kinase activity in patients with necrotizing myopathy. Arthritis Rheum 2011; 63:1961-1971
29. Jeon YL, Kim MH, Lee WI, Kang SY. Comparison of indirect immunofluorescence and line immunoassay for autoantibody detection. Clin Exp Rheumatol 2013; 31:84-90
30. Muro Y, Sugiura K, Hoshino K, Akiyama M. Disappearance of anti-MDA-5 autoantibodies in clinically amyopathic DM/interstitial lung disease during disease remission. Rheumatology 2012; 51:800-804
31. Kobayashi I, Okura Y, Yamada H. Anti-melanoma differentiation-Associated gene 5 antibody is a diagnostic and predictive marker for interstitial lung diseases associated with juvenile dermatomyositis. J Pediatr 2011; 158: 675-677
32. Sato S, Kobayashi N, Yamazaki K, Suzuki Y. Clinical utility of anti-CADM-140/ melanoma differentiation-Associated gene 5 autoantibody titres in patients with juvenile dermatomyositis and rapidly progressive interstitial lung disease [Abstract 292]. In: American College of Rheumatology 76th Annual Meeting; November 2012; S128
33. Stone KB, Oddis CV, Fertig N, et al. Anti-Jo-1 antibody levels correlate with disease activity in idiopathic inflammatory myopathy. Arthritis Rheum 2007; 56:3125-3131
34. Aggarwal R, Oddis CV, Bandos A, et al. Effect of B cell depletion therapy with rituximab on myositis associated autoantibody levels in idiopathic inflammatory myopathy. In: American College of Rheumatology 76th Annual Meeting; 2012. S325
35. .Werner JL, Christopher-Stine L, Ghazarian SR, et al. Antibody levels correlate with creatine kinase levels and strength in anti3-hydroxy-3- methylglutarylcoenzyme A reductase-Associated autoimmune myopathy. Arthritis Rheum 2012; 64:4087-4093
36. Aggarwal R, Fertig N, Goudeau D, et al. Anti-Transcription intermediary factor 1-gamma autoantibody detection by ELISA and immunoprecipitation in a prospective myositis cohort: Predictive value for cancer associated myositis. In: American College of Rheumatology 76th Annual Meeting. S824
37. Chahin N, Engel AG. Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM. Neurology 2008; 70:418-424
38. Mammen AL. Dermatomyositis and polymyositis: Clinical presentation, autoantibodies, and pathogenesis. Ann N Y Acad Sci 2010; 1184:134-153
39. Gordon PA, Winer JB, Hoogendijk JE, Choy E. Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis. Cochrane Database Syst Rev) 2012; (8); CD003643
40. Aggarwal R, Reed AM, Ascherman DP, et al. Clinical and serologic predictors of response in rituximab-Treated refractory adult and juvenile dermatomyositis and polymyositis: The RIM study. In: American College of Rheumatology 76th Annual Meeting; Washington, DC; 2012. S682